Full Text of SR1369 100th General Assembly
SR1369 100TH GENERAL ASSEMBLY |
| | SR1369 | | LRB100 19627 ALS 34900 r |
|
| 1 | | SENATE RESOLUTION
| 2 | | WHEREAS, Eczema is a set of skin conditions that cause red, | 3 | | itchy, and inflamed skin, and has profound medical, | 4 | | psychosocial, and economic effects on patients, families, and | 5 | | their communities; and
| 6 | | WHEREAS, The prevalence of eczema in the United States is | 7 | | 10.1 percent; and
| 8 | | WHEREAS, Eczema affects over 31.6 million children and | 9 | | adults in the United States alone; and
| 10 | | WHEREAS, Eczema's medical effects include dry, cracked, | 11 | | and scaly skin, incessant itch, chronic pain, and sleep | 12 | | deprivation; and
| 13 | | WHEREAS, 41.5 percent of adult eczema patients report | 14 | | having a co-occurring diagnosis of depression and 47.9 percent | 15 | | report having a co-occurring diagnosis of asthma; and
| 16 | | WHEREAS, Adults and children with eczema also frequently | 17 | | exhibit comorbidities like asthma, allergic rhinitis, food | 18 | | allergies, ADHD, bacterial and viral infections, and | 19 | | hypertension; and
|
| | | SR1369 | - 2 - | LRB100 19627 ALS 34900 r |
|
| 1 | | WHEREAS, Eczema's disease burden also includes anxiety, | 2 | | stress on social and intimate relationships, increased | 3 | | suicidal ideation, delayed developmental achievement, reduced | 4 | | self-esteem, restrictions on diet and exercise, extensive | 5 | | caregiver burdens, and challenges with medication adherence; | 6 | | and
| 7 | | WHEREAS, Eczema results in missed days of school and work | 8 | | for patients and caregivers, disability, and reduced ability | 9 | | within a patient's chosen profession, unemployment and | 10 | | underemployment, and other opportunity costs; and
| 11 | | WHEREAS, The direct medical costs of the three most common | 12 | | types of eczema exceed $2.17 billion, and the indirect medical | 13 | | costs exceed $927 million; and
| 14 | | WHEREAS, Two-thirds of eczema patients report experiencing | 15 | | significant access barriers, including high out-of-pocket | 16 | | costs and insurance requirements that delay patients' access to | 17 | | medications; and
| 18 | | WHEREAS, There is no cure for eczema, but emerging | 19 | | technologies and medications promise a much brighter future for | 20 | | eczema patients; therefore, be it
| 21 | | RESOLVED, BY THE SENATE OF THE ONE HUNDREDTH GENERAL |
| | | SR1369 | - 3 - | LRB100 19627 ALS 34900 r |
|
| 1 | | ASSEMBLY OF THE STATE OF ILLINOIS, that the month of October | 2 | | 2018 is designated as Eczema Awareness Month and residents are | 3 | | encourage to show support for Eczema Awareness.
|
|